Literature DB >> 21173019

Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma.

Karen Fröhlich, Julia U Holle, Peer M Aries, Wolfgang L Gross, Frank Moosig.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21173019     DOI: 10.1136/ard.2010.133256

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  12 in total

Review 1.  New Trials in Lupus and where Are we Going.

Authors:  Aikaterini Thanou; Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2018-05-03       Impact factor: 4.592

2.  Oxathiazolones Selectively Inhibit the Human Immunoproteasome over the Constitutive Proteasome.

Authors:  Hao Fan; Nicholas G Angelo; J David Warren; Carl F Nathan; Gang Lin
Journal:  ACS Med Chem Lett       Date:  2014-02-03       Impact factor: 4.345

3.  Immunoproteasome β5i-Selective Dipeptidomimetic Inhibitors.

Authors:  Pradeep K Singh; Hao Fan; Xiuju Jiang; Lei Shi; Carl F Nathan; Gang Lin
Journal:  ChemMedChem       Date:  2016-08-25       Impact factor: 3.466

4.  Non-lymphoma hematological malignancies in systemic lupus erythematosus.

Authors:  Mary Lu; Sasha Bernatsky; Rosalind Ramsey-Goldman; Michelle Petri; Susan Manzi; Murray B Urowitz; Dafna Gladman; Paul R Fortin; Ellen M Ginzler; Edward Yelin; Sang-Cheol Bae; Daniel J Wallace; Soren Jacobsen; Mary Anne Dooley; Christine A Peschken; Graciela S Alarcón; Ola Nived; Lena Gottesman; Lindsey A Criswell; Gunnar Sturfelt; Lene Dreyer; Jennifer L Lee; Ann E Clarke
Journal:  Oncology       Date:  2013-10-02       Impact factor: 2.935

Review 5.  Haematological manifestations of lupus.

Authors:  Anum Fayyaz; Ann Igoe; Biji T Kurien; Debashish Danda; Judith A James; Haraldine A Stafford; R Hal Scofield
Journal:  Lupus Sci Med       Date:  2015-03-03

Review 6.  Successful treatment of severe immune hemolytic anemia after allogeneic stem cell transplantation with bortezomib: report of a case and review of literature.

Authors:  Sakura Hosoba; David L Jaye; Cynthia Cohen; John D Roback; Edmund K Waller
Journal:  Transfusion       Date:  2014-08-25       Impact factor: 3.157

7.  Pharmacodynamic monitoring of (immuno)proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nephritis and myocarditis.

Authors:  Karina A de Groot; Michel Tsang A Sjoe; Denise Niewerth; Jacqueline Cloos; Jonathan L Blank; Hans W M Niessen; Sonja Zweegman; Alexandre E Voskuyl; Gerrit Jansen; Joost W van der Heijden
Journal:  Lupus Sci Med       Date:  2015-12-18

8.  Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity.

Authors:  Tomoko Ikeda; Hiroshi Fujii; Masato Nose; Yukiko Kamogawa; Tsuyoshi Shirai; Yuko Shirota; Tomonori Ishii; Hideo Harigae
Journal:  Arthritis Res Ther       Date:  2017-08-11       Impact factor: 5.156

Review 9.  Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity.

Authors:  Henrik E Mei; Stefanie Schmidt; Thomas Dörner
Journal:  Arthritis Res Ther       Date:  2012-11-08       Impact factor: 5.156

10.  Analyzing pathogenic (double-stranded (ds) DNA-specific) plasma cells via immunofluorescence microscopy.

Authors:  Oliver Winter; Stephanie Musiol; Melissa Schablowsky; Qingyu Cheng; Laleh Khodadadi; Falk Hiepe
Journal:  Arthritis Res Ther       Date:  2015-10-21       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.